PharmiWeb3d
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
pharmaphorum2d
Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial
It's a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion ...
pharmaphorum2d
Bayer takes lung cancer therapy hope into phase 3
Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to ...
Oncology Nursing News17h
Camrelizumab Plus Rivoceranib Receives Second CRL in HCC
The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...
Medscape2d
HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Biosimilar Monoclonal Antibodies Market Size, Share, Forecast To 2033
Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
Business Wire2d
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...
European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX1...
Shanghai Henlius Biotech, Inc. (2696) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has valida ...
Yahoo Finance4d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy (CRT) (LBA4). SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with ...
Le Lézard4d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...
Medscape6d
Everything you need to know about At-Home Cancer Treatment
"COA strongly opposes home infusion of chemotherapy, cancer immunotherapy, and supportive drugs. It is not an appropriate option for patients with cancer." ...
oncnursingnews4d
Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET
The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs. Cabozantinib received FDA approval for use ...